A study on the relationship between homocysteine and diabetic nephropathy in rats

Pharmacological Research

Volumn 45, Issue 3, 2002, Pages 249-252

  Unlucerci, Yeşim ^a   Bekpinar, Selda ^a   Gürdöl, Figen ^a   Seferog̀lu, Gülay ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Advanced glycation end products; Diabetic nephropathy; Glycosaminoglycans; Homocysteine

Indexed keywords

ADVANCED GLYCATION END PRODUCT; AMINOGUANIDINE; BUFFER; CITRIC ACID; CREATININE; DRINKING WATER; HOMOCYSTEINE; METHYLENE BLUE; PLASMA PROTEIN; STREPTOZOCIN; THIOL DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; GLUCOSE BLOOD LEVEL; HEART; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; NONHUMAN; PATHOGENESIS; PENILE BLOOD VESSEL; PRIORITY JOURNAL; PROTEIN URINE LEVEL; QUANTITATIVE ANALYSIS; RAT; SPECTROPHOTOMETRY; SYMPTOMATOLOGY; URINALYSIS; VEIN PUNCTURE;

EID: 0036445328     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1006/phrs.2001.0942     Document Type: Article

References (32)

1. McCully KS. Homocysteine and vascular disease. Nat Med 1996; 2: 386-9.
2. Evans RW, Shaten BJ, Hempel JD, Cutler JA, Kuller LH. Homocyst(e)ine and risk of cardiovascular disease in the multiple risk factor intervention trial. Arterioscler Thromb Vasc Biol 1997; 17: 1947-53.
3. Lentz SR. Minireview: Homocysteine and vascular dysfunction. Life Sci 1997; 61: 1205-15.
4. Bostom AG, Lathrop AG. Hyperhomocysteinemia in end-stage renal disease: Prevalence, etiology, and potential relationship to arteriosclerotic outcomes. Kidney Int 1997; 52: 10-20.
5. Arnadottir M, Hultberg B, Nilsson-Ehle P, Thysell H. The effect of reduced glomerular filtration rate on plasma total homocysteine concentration. Scan J Clin Lab Invest 1996; 56: 41-6.
6. Hofman MA et al. Hyperhomocyst(e)inemia and endothelial dysfunction in IDDM. Diabetes Care 1997; 20: 1880-6.
7. Chico A, Perez A, Cordoba A, Arcelus R, Carreras G, de Leiva A, Gonzales-Sastre F, Blanco-Vaca F. Plasma homocystein is related to albumin excretion rate in patients with diabetes mellitus: A new link between diabetic nephropathy and cardiovascular disease? Diabetologia 1998; 41: 684-93.
8. Jakubowski H. Homocysteine thiolactone: Metabolic origin and protein homocysteinylation in humans. J Nutr 2000; 130: 377S-81S.
9. Niva T, Miyazaki T, Katsuzaki T, Tatemichi N, Takei Y. Serum levels of 3-deoxyglucosone and tissue contents of advanced glycation end products are increased in streptozotocin-induced diabetic rats with nephropathy. Nephron 1996; 74: 580-5.
10. Lee HB, Cha MK, Song KI, Kim JH, Lee EY, Kim SI, Kim J, Yoo MH. Pathogenic role of advanced glycosylation end products in diabetic nephropathy. Kidney Int 1997; 52: 60-5.
11. Ellman GL. Tissue sulfhydryl groups. Arch Biochem Biophys 1959; 82: 70-7.
12. Bauer JD. Carbohydrate and nitrogen compounds. In: Clinical Laboratory Methods. St. Louis: Mosby, 1982: 501-2.
13. Faulkner WR, King JW. Renal function. In: Fundamentals of Clinical Chemistry. Norbert W, Tietz WB, eds. Philadelphia, PA: Saunders, 1976: 994-9.
14. Dyson EH, Will EJ, Davison AM, O'Malleey AH, Shepherd HT, Jones RG. Use of the urinary protein creatinine index to assess proteinuria in renal transplant patients. Nephrol Dial Transplant 1992; 7: 450-2.
15. van de Lest CH, Versteeg EM, Veerkamp JH, van Kuppevelt TH. A spectrophotometric method for the determination of heparan sulphate. Biochim Biophys Acta 1994; 1201: 305-11.
16. Vester B, Rasmussen K. High performance liquid chromatography method for rapid and accurate determination of homocysteine in plasma and serum. Eur J Clin Chem Clin Biochem 1991; 29: 549-54.
17. Ubbink JB, Vermaak WHJ, Bissbort S. Rapid high performance liquid chromatographic assay for total homocysteine levels in human serum. J Chromatogr 1991; 565: 441-6.
18. Smulders YM, Rakic M, Slaats EH, Treskes M, Sijbrands EJ, Odekerken DA, Stehouwer CDA, Silberbusch J. Fasting and post-methionine homocysteine levels in NIDDM. Diabetes Care 1999; 22: 125-32.
19. Stehouwer CDA, Gall MA, Hougaard P, Jacobs C, Parving HH. Plasma homocysteine concentration predicts mortality in non-inslin-dependent diabetic patients with and without albuminuria. Kidney Int 1999; 55: 308-14.
20. Robillon JF, Canivet B, Candito M, Sadoul JL, Jullien D, Morand P, Chambon P, Freychet P. Type I diabetes mellitus and homocyst(e)ine. Diabetes Metab 1994; 20: 494-6.
21. Jacobs RL, House JD, Brosnan ME, Brosnan JT. Effects of streptozotocin-induced diabetes and of insulin treatment on homocysteine metabolism in the rat. Diabetes 1998; 47: 1967-70.
22. Brownlee M, Vlassara H, Kooney T, Ulrich P, Cerami A. Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science 1986; 232: 1629-32.
23. Huijberts MSP, Wolffenbuttel BHR, Struijker-Boudier HAJ, Crijns FRL. Aminoguanidine treatment increases elasticity and decreases fluid retention of large arteries from diabetic rats. J Clin Invest 1993; 92: 1407-11.
24. Odetti PR, Borgoglio A, De Pascale A, Rolandi R, Adezati L. Prevention of diabetes increased aging effect on rat collagen-linked fluorescence by aminoguanidine and rutin. Diabetes 1990; 39: 796-801.
25. + ATPase in rats. Pharmacol Res 2001; 44: 95-8.
26. House JD, Brosnan ME, Brosnan JT. Renal uptake and excretion of homocysteine in rats with acute hyperhomocysteinemia. Kidney Int 1998; 54: 1601-7.
27. Bostom AG, Brosnan JT, Hall B, Nadeau M, Selhub J. Net uptake of plasma homocysteine by the rat kidney in vivo. Atherosclerosis 1995; 116: 59-62.
28. McKeever MP, Weir DG, Molloy A, Scott JM. Betaine-homocysteine methyltransferase: Organ distribution in man, pig and rat and subcellular distribution in the rat. Clin Sci 1991; 81: 551-6.
29. Lentz SR. Minireview: Homocysteine and vascular dysfunction. Life Sci 1997; 61: 1205-15.
30. Stipanuk MH, De La Rosa J, Hirschberger LL. Catabolism of cyst(e)ine by rat renal cortical tubules. J Nutr 1990; 120: 450-8.
31. Barak AJ, Beckenhauer HC. The influence of ethanol on hepatic transmethylation. Alcohol Alcohol 1988; 23: 73-7.
32. Solini A, Vergnani L, Ricci F, Crepaldi G. Glycosaminoglycans delay the progression of nephropathy in NIDDM. Diabetes Care 1997; 20: 819-23.